Buck Institute: "Global Leader in Revolutionary Stem Cell Technology"
Associate Professor, Xianmin Zeng PhD, from the Buck Institute and a LLHF Grant recipient has developed new stem cell therapy for Parkinson's Disease which provides a method to reproduce the required amount of clinical grade neurons essential for human trials. She also confirmed this technique could be created in a good manufacturing practice facility which is necessary for clinical trials.
Over the last year Dr. Zeng has been traveling around the world to help other countries coordinate stem cell manufacturing procedures as well.
"The global collaboration we are doing will get others the tools they need so that they don't have to start from the beginning. This should speed up the search for new therapies."